GSK Opens First Asian Vaccine Manufacturing Plant In Singapore
This article was originally published in PharmAsia News
Executive Summary
HONG KONG - Fifty years after it first started operating in Singapore, GlaxoSmithKline opened its first primary vaccine manufacturing facility in Asia in Singapore June 9
You may also be interested in...
Pfizer And GSK Use Novel Funding Mechanism To Send Blockbuster Vaccines To World's Poorest Countries
Pfizer and GlaxoSmithKline have agreed, after four years of negotiations, to supply their leading pneumococcal vaccines at significantly reduced prices to the world's poorest countries, signaling the first use of a novel funding mechanism that could create similar deals to bring new drugs to developing countries
Pfizer And GSK Use Novel Funding Mechanism To Send Blockbuster Vaccines To World's Poorest Countries
Pfizer and GlaxoSmithKline have agreed, after four years of negotiations, to supply their leading pneumococcal vaccines at significantly reduced prices to the world's poorest countries, signaling the first use of a novel funding mechanism that could create similar deals to bring new drugs to developing countries
Pfizer And GSK Use Novel Funding Mechanism To Send Blockbuster Vaccines To World's Poorest Countries
Pfizer and GSK have promised to supply 30 million doses each for the next 10 years. The first 20 percent of the supply will be sold for $7 per dose, while the remaining supply of Pfizer's Prevenar 13 and GSK's Synflorix will be sold for $3.50.